Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00301756 · OUTCOME

Time to Disease Progression (Low Malignant Potential or Micropapillary / Borderline Ovarian Tumour Group)

Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors · Source last updated 2018-08-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Up to 5 years

What was measured

Assessed by RECIST criteria. Summarized using summary statistics, such as the mean, median, counts and proportion.

Groups in this outcome

Treatment (Enzyme Inhibitor Therapy)

Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. belinostat: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Enzyme Inhibitor Therapy)14

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Enzyme Inhibitor Therapy)13.4Not reported5.6NAA value is not available because the upper range was not reached
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        A value is not available because the upper range was not reached
        group Id
        OG000
        lower Limit
        5.6
        upper Limit
        NA
        value
        13.4
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    units
    Participants
description
Assessed by RECIST criteria. Summarized using summary statistics, such as the mean, median, counts and proportion.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients receive belinostat IV over 30 minutes on days 1-5. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. belinostat: Given IV
    id
    OG000
    title
    Treatment (Enzyme Inhibitor Therapy)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 5 years
title
Time to Disease Progression (Low Malignant Potential or Micropapillary / Borderline Ovarian Tumour Group)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice